Autoimmune Epilepsy

Khalil S. Husari, Divyanshu Dubey

Research output: Contribution to journalArticle

Abstract

The field of autoimmune epilepsy has evolved substantially in the last few decades with discovery of several neural autoantibodies and improved mechanistic understanding of these immune-mediated syndromes. A considerable proportion of patients with epilepsy of unknown etiology have been demonstrated to have an autoimmune cause. The majority of the patients with autoimmune epilepsy usually present with new-onset refractory seizures along with subacute progressive cognitive decline and behavioral or psychiatric dysfunction. Neural specific antibodies commonly associated with autoimmune epilepsy include leucine-rich glioma-inactivated protein 1 (LGI1), N-methyl-d-aspartate receptor (NMDA-R), and glutamic acid decarboxylase 65 (GAD65) IgG. Diagnosis of these cases depends on the identification of the clinical syndrome and ancillary studies including autoantibody evaluation. Predictive models (Antibody Prevalence in Epilepsy and Encephalopathy [APE2] and Response to Immunotherapy in Epilepsy and Encephalopathy [RITE2] scores) based on clinical features and initial neurological assessment may be utilized for selection of cases for autoimmune epilepsy evaluation and management. In this article, we will review the recent advances in autoimmune epilepsy and provide diagnostic and therapeutic algorithms for epilepsies with suspected autoimmune etiology.

Original languageEnglish (US)
Pages (from-to)685-702
Number of pages18
JournalNeurotherapeutics
Volume16
Issue number3
DOIs
StatePublished - Jul 15 2019

Fingerprint

Epilepsy
Brain Diseases
Autoantibodies
Glutamate Decarboxylase
Antibodies
Leucine
Glioma
Immunotherapy
Psychiatry
Seizures
Immunoglobulin G
Proteins

Keywords

  • Autoimmune limbic encephalitis
  • Diagnosis
  • Epilepsy
  • Immunotherapy

ASJC Scopus subject areas

  • Pharmacology
  • Clinical Neurology
  • Pharmacology (medical)

Cite this

Autoimmune Epilepsy. / Husari, Khalil S.; Dubey, Divyanshu.

In: Neurotherapeutics, Vol. 16, No. 3, 15.07.2019, p. 685-702.

Research output: Contribution to journalArticle

Husari, Khalil S. ; Dubey, Divyanshu. / Autoimmune Epilepsy. In: Neurotherapeutics. 2019 ; Vol. 16, No. 3. pp. 685-702.
@article{4540a3e6f4294318806ffc30b5c34a0e,
title = "Autoimmune Epilepsy",
abstract = "The field of autoimmune epilepsy has evolved substantially in the last few decades with discovery of several neural autoantibodies and improved mechanistic understanding of these immune-mediated syndromes. A considerable proportion of patients with epilepsy of unknown etiology have been demonstrated to have an autoimmune cause. The majority of the patients with autoimmune epilepsy usually present with new-onset refractory seizures along with subacute progressive cognitive decline and behavioral or psychiatric dysfunction. Neural specific antibodies commonly associated with autoimmune epilepsy include leucine-rich glioma-inactivated protein 1 (LGI1), N-methyl-d-aspartate receptor (NMDA-R), and glutamic acid decarboxylase 65 (GAD65) IgG. Diagnosis of these cases depends on the identification of the clinical syndrome and ancillary studies including autoantibody evaluation. Predictive models (Antibody Prevalence in Epilepsy and Encephalopathy [APE2] and Response to Immunotherapy in Epilepsy and Encephalopathy [RITE2] scores) based on clinical features and initial neurological assessment may be utilized for selection of cases for autoimmune epilepsy evaluation and management. In this article, we will review the recent advances in autoimmune epilepsy and provide diagnostic and therapeutic algorithms for epilepsies with suspected autoimmune etiology.",
keywords = "Autoimmune limbic encephalitis, Diagnosis, Epilepsy, Immunotherapy",
author = "Husari, {Khalil S.} and Divyanshu Dubey",
year = "2019",
month = "7",
day = "15",
doi = "10.1007/s13311-019-00750-3",
language = "English (US)",
volume = "16",
pages = "685--702",
journal = "Neurotherapeutics",
issn = "1933-7213",
publisher = "Springer New York",
number = "3",

}

TY - JOUR

T1 - Autoimmune Epilepsy

AU - Husari, Khalil S.

AU - Dubey, Divyanshu

PY - 2019/7/15

Y1 - 2019/7/15

N2 - The field of autoimmune epilepsy has evolved substantially in the last few decades with discovery of several neural autoantibodies and improved mechanistic understanding of these immune-mediated syndromes. A considerable proportion of patients with epilepsy of unknown etiology have been demonstrated to have an autoimmune cause. The majority of the patients with autoimmune epilepsy usually present with new-onset refractory seizures along with subacute progressive cognitive decline and behavioral or psychiatric dysfunction. Neural specific antibodies commonly associated with autoimmune epilepsy include leucine-rich glioma-inactivated protein 1 (LGI1), N-methyl-d-aspartate receptor (NMDA-R), and glutamic acid decarboxylase 65 (GAD65) IgG. Diagnosis of these cases depends on the identification of the clinical syndrome and ancillary studies including autoantibody evaluation. Predictive models (Antibody Prevalence in Epilepsy and Encephalopathy [APE2] and Response to Immunotherapy in Epilepsy and Encephalopathy [RITE2] scores) based on clinical features and initial neurological assessment may be utilized for selection of cases for autoimmune epilepsy evaluation and management. In this article, we will review the recent advances in autoimmune epilepsy and provide diagnostic and therapeutic algorithms for epilepsies with suspected autoimmune etiology.

AB - The field of autoimmune epilepsy has evolved substantially in the last few decades with discovery of several neural autoantibodies and improved mechanistic understanding of these immune-mediated syndromes. A considerable proportion of patients with epilepsy of unknown etiology have been demonstrated to have an autoimmune cause. The majority of the patients with autoimmune epilepsy usually present with new-onset refractory seizures along with subacute progressive cognitive decline and behavioral or psychiatric dysfunction. Neural specific antibodies commonly associated with autoimmune epilepsy include leucine-rich glioma-inactivated protein 1 (LGI1), N-methyl-d-aspartate receptor (NMDA-R), and glutamic acid decarboxylase 65 (GAD65) IgG. Diagnosis of these cases depends on the identification of the clinical syndrome and ancillary studies including autoantibody evaluation. Predictive models (Antibody Prevalence in Epilepsy and Encephalopathy [APE2] and Response to Immunotherapy in Epilepsy and Encephalopathy [RITE2] scores) based on clinical features and initial neurological assessment may be utilized for selection of cases for autoimmune epilepsy evaluation and management. In this article, we will review the recent advances in autoimmune epilepsy and provide diagnostic and therapeutic algorithms for epilepsies with suspected autoimmune etiology.

KW - Autoimmune limbic encephalitis

KW - Diagnosis

KW - Epilepsy

KW - Immunotherapy

UR - http://www.scopus.com/inward/record.url?scp=85068331286&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068331286&partnerID=8YFLogxK

U2 - 10.1007/s13311-019-00750-3

DO - 10.1007/s13311-019-00750-3

M3 - Article

C2 - 31240596

AN - SCOPUS:85068331286

VL - 16

SP - 685

EP - 702

JO - Neurotherapeutics

JF - Neurotherapeutics

SN - 1933-7213

IS - 3

ER -